Markets:

Overview

News

Currencies

International

Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

22.84 +0.11 (+0.46%)

Streaming Delayed Price Updated: 3:19 PM EDT, Jun 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know ↗

June 15, 2022

Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

June 15, 2022

Jefferies raised Tapestry, Inc. (NYSE: TPR) price target from $30 to $45. Tapestry shares rose 2.2% to close at $31.60 on Tuesday.

Via Benzinga

Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark ↗

June 08, 2022

On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75.

Via Investor's Business Daily

Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82 ↗

June 08, 2022

Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock.

Via Investor's Business Daily

Vertex Pharmaceuticals Receives Composite Rating Upgrade ↗

May 24, 2022

The IBD SmartSelect Composite Rating for VRTX stock increased from 94 to 96 Tuesday, a sign of strong fundamentals.

Via Investor's Business Daily

Expert Ratings For Pacira BioSciences ↗

November 05, 2021

Within the last quarter, Pacira BioSciences (NASDAQ:PCRX) has observed the...

Via Benzinga

Pacira BioSciences's Return on Invested Capital Overview ↗

May 20, 2022

Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters.

Via Benzinga

Gilead Stock Earns Rating Upgrade After Quick Turnaround ↗

May 19, 2022

A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?

Via Investor's Business Daily

Pacira BioSciences: Q1 Earnings Insights ↗

May 04, 2022

Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 28, 2022

Pacira BioSciences (NASDAQ:PCRX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗

April 14, 2022

On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.

Via Investor's Business Daily

28 Biggest Movers From Yesterday ↗

April 12, 2022

Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire...

Via Benzinga

Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92 ↗

April 07, 2022

On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.

Via Investor's Business Daily

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

April 06, 2022

On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago.

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

April 04, 2022

Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.

Via Investor's Business Daily

Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗

March 25, 2022

Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.

Via Investor's Business Daily

Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating ↗

March 23, 2022

Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.

Via Investor's Business Daily

Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating ↗

March 08, 2022

Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82.

Via Investor's Business Daily

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating ↗

February 07, 2022

The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.

Via Investor's Business Daily

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

PCRX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Earnings Scheduled For November 3, 2021 ↗

November 03, 2021

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher ↗

October 11, 2021

Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...

Via Talk Markets

Topics Stocks

Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition ↗

October 11, 2021

Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.